Research from the University of Mississippi, published in the Journal of Managed Care and Specialty Pharmacy and reported this week, restates a conclusion payers have been circling for two years: GLP-1 obesity drugs such as semaglutide and tirzepatide deliver enough health benefit to justify their price, and covering every eligible patient would still overwhelm insurer and public budgets.1 ScienceDaily 2026-07-23 University of Mississippi research published in the Journal of Managed Care and Specialty Pharmacy finds GLP-1 drugs deliver strong health value yet covering millions of eligible patients could overwhelm insurance budgets. Open source 2 Journal of Managed Care & Specialty Pharmacy 2026-06-01 Ramachandran, Urick and Thomas find weight loss drugs cost effective but high budget impact, note lower real world persistence with weight regain after discontinuation, cost offsets mainly in patients with obesity and diabetes on high potency injectables, and recommend targeted authorization, paired lifestyle programs, no arbitrary time limits and new payment models. Open source The arithmetic behind that is not subtle. ICER's evidence report put annual net prices at $6,829 for injectable semaglutide and $7,973 for tirzepatide, and found that fewer than 1% of eligible US patients could be treated before spending crossed its annual budget impact threshold of $880 million.4 ICER 2025-10-29 Net annual prices of $6,829 for injectable semaglutide and $7,973 for tirzepatide; health benefit price benchmarks of $9,100 to $12,500, $8,300 to $11,400 and $11,500 to $15,800; fewer than 1% of eligible patients treatable within an $880 million annual budget impact threshold; access and affordability alert issued. Open source Roughly 40% of American adults have obesity.3 University of Mississippi 2026-07-22 ICER's 2026 budget impact threshold is $821 million and GLP-1 spending exceeds it even at low uptake; about 40% of American adults have obesity; trials compared GLP-1s against lifestyle management rather than no treatment; the FDA has issued warning letters about compounded GLP-1s. Open source We assess with high confidence that the binding constraint on GLP-1 access is not evidence of benefit and not the per patient price, but the size of the eligible population multiplied by any price a manufacturer would accept.
Two different questions, routinely confused
Cost effectiveness asks whether the health gained from treating one patient is worth what that patient's treatment costs. Budget impact asks whether a payer can write the total check in a given year. A drug can pass the first test and fail the second, and GLP-1s are the clearest live example. ICER's draft analysis put the cost per quality adjusted life year at $53,400 for tirzepatide, $61,400 for injectable semaglutide and $69,300 for the oral form, all inside the range health economists normally treat as good value.5 Pharmaceutical Commerce 2025-10-30 ICER draft cost per quality adjusted life year of $53,400 for tirzepatide, $61,400 for injectable semaglutide and $69,300 for oral semaglutide, with weight loss of 17.8% to 20.8%, 14% to 17% and 11.4% respectively, and a note that additional treatment options may help close the treatment gap. Open source ICER went further and calculated health benefit price benchmarks, the highest prices it considered justifiable, of $9,100 to $12,500 for injectable semaglutide, $8,300 to $11,400 for oral semaglutide and $11,500 to $15,800 for tirzepatide.4 ICER 2025-10-29 Net annual prices of $6,829 for injectable semaglutide and $7,973 for tirzepatide; health benefit price benchmarks of $9,100 to $12,500, $8,300 to $11,400 and $11,500 to $15,800; fewer than 1% of eligible patients treatable within an $880 million annual budget impact threshold; access and affordability alert issued. Open source Those benchmarks sit above the current net prices. On the value test, these drugs are not merely passing, they are priced below what the modeled benefit would support.4 ICER 2025-10-29 Net annual prices of $6,829 for injectable semaglutide and $7,973 for tirzepatide; health benefit price benchmarks of $9,100 to $12,500, $8,300 to $11,400 and $11,500 to $15,800; fewer than 1% of eligible patients treatable within an $880 million annual budget impact threshold; access and affordability alert issued. Open source
Then the same report issued an access and affordability alert, because the eligible pool is enormous and the threshold is fixed.4 ICER 2025-10-29 Net annual prices of $6,829 for injectable semaglutide and $7,973 for tirzepatide; health benefit price benchmarks of $9,100 to $12,500, $8,300 to $11,400 and $11,500 to $15,800; fewer than 1% of eligible patients treatable within an $880 million annual budget impact threshold; access and affordability alert issued. Open source Sujith Ramachandran of the University of Mississippi, an author of the commentary, put ICER's 2026 budget impact threshold at $821 million and said GLP-1 spending passes it even at low uptake.3 University of Mississippi 2026-07-22 ICER's 2026 budget impact threshold is $821 million and GLP-1 spending exceeds it even at low uptake; about 40% of American adults have obesity; trials compared GLP-1s against lifestyle management rather than no treatment; the FDA has issued warning letters about compounded GLP-1s. Open source Note the structure of the failure: lowering the price does not fix it, it only changes how far past the threshold you land. At $7,000 a year, one million treated patients is $7 billion. The threshold is a fraction of one percent of that population.4 ICER 2025-10-29 Net annual prices of $6,829 for injectable semaglutide and $7,973 for tirzepatide; health benefit price benchmarks of $9,100 to $12,500, $8,300 to $11,400 and $11,500 to $15,800; fewer than 1% of eligible patients treatable within an $880 million annual budget impact threshold; access and affordability alert issued. Open source
Why the savings story keeps underdelivering
The usual reconciliation is that drug spending now buys avoided spending later: fewer heart attacks, less diabetes care, fewer joint replacements. The Mississippi commentary is skeptical of that offset as a near term budget line. It reports that real world persistence on these drugs is lower than in clinical trials, which produces frequent weight regain after discontinuation, and that cost offsets showed up mainly for patients who had both obesity and diabetes and were taking high potency injectables, while patients with obesity alone often generated higher total spending.2 Journal of Managed Care & Specialty Pharmacy 2026-06-01 Ramachandran, Urick and Thomas find weight loss drugs cost effective but high budget impact, note lower real world persistence with weight regain after discontinuation, cost offsets mainly in patients with obesity and diabetes on high potency injectables, and recommend targeted authorization, paired lifestyle programs, no arbitrary time limits and new payment models. Open source Its blunt guidance to managed care organizations is to expect value but not near term savings.2 Journal of Managed Care & Specialty Pharmacy 2026-06-01 Ramachandran, Urick and Thomas find weight loss drugs cost effective but high budget impact, note lower real world persistence with weight regain after discontinuation, cost offsets mainly in patients with obesity and diabetes on high potency injectables, and recommend targeted authorization, paired lifestyle programs, no arbitrary time limits and new payment models. Open source
A second point cuts at how the value estimate is built. Ramachandran notes that the trials did not compare these drugs against no treatment, they compared them against lifestyle management, meaning the modeled benefit assumes the wrapper of dietitian access and structured support comes with the prescription.3 University of Mississippi 2026-07-22 ICER's 2026 budget impact threshold is $821 million and GLP-1 spending exceeds it even at low uptake; about 40% of American adults have obesity; trials compared GLP-1s against lifestyle management rather than no treatment; the FDA has issued warning letters about compounded GLP-1s. Open source We assess with moderate confidence that plans buying the molecule without that wrapper will underperform the cost effectiveness estimates they are citing to justify coverage, because the comparator embedded in the evidence is not what those plans are actually delivering.
Who gains, who loses
Novo Nordisk and Eli Lilly gain on the value finding and lose on the volume constraint. A regulator style body telling the market that current net prices sit below the justifiable benchmark is a strong defense against price cutting pressure.4 ICER 2025-10-29 Net annual prices of $6,829 for injectable semaglutide and $7,973 for tirzepatide; health benefit price benchmarks of $9,100 to $12,500, $8,300 to $11,400 and $11,500 to $15,800; fewer than 1% of eligible patients treatable within an $880 million annual budget impact threshold; access and affordability alert issued. Open source What they cannot obtain from that finding is unrestricted coverage, because the payer's problem is arithmetic rather than persuasion.4 ICER 2025-10-29 Net annual prices of $6,829 for injectable semaglutide and $7,973 for tirzepatide; health benefit price benchmarks of $9,100 to $12,500, $8,300 to $11,400 and $11,500 to $15,800; fewer than 1% of eligible patients treatable within an $880 million annual budget impact threshold; access and affordability alert issued. Open source
Commercial insurers, self funded employers and state Medicaid programs carry the loss, and they carry it asymmetrically: the spending is immediate and the modeled health return accrues over years, some of it after the member has changed plans. That timing mismatch is the mechanism behind restrictive prior authorization, and the commentary's own recommendations, targeted authorization, coupling drugs to lifestyle programs, avoiding arbitrary time limits, and new payment models, are an attempt to manage it rather than escape it.2 Journal of Managed Care & Specialty Pharmacy 2026-06-01 Ramachandran, Urick and Thomas find weight loss drugs cost effective but high budget impact, note lower real world persistence with weight regain after discontinuation, cost offsets mainly in patients with obesity and diabetes on high potency injectables, and recommend targeted authorization, paired lifestyle programs, no arbitrary time limits and new payment models. Open source
Patients split along two lines. Those with obesity plus diabetes on high potency injectables are the group where the offset evidence is strongest, and they are the most defensible to cover.2 Journal of Managed Care & Specialty Pharmacy 2026-06-01 Ramachandran, Urick and Thomas find weight loss drugs cost effective but high budget impact, note lower real world persistence with weight regain after discontinuation, cost offsets mainly in patients with obesity and diabetes on high potency injectables, and recommend targeted authorization, paired lifestyle programs, no arbitrary time limits and new payment models. Open source Patients with obesity alone are the ones rationing will reach first, since they are both the larger group and the weaker case on near term spending.2 Journal of Managed Care & Specialty Pharmacy 2026-06-01 Ramachandran, Urick and Thomas find weight loss drugs cost effective but high budget impact, note lower real world persistence with weight regain after discontinuation, cost offsets mainly in patients with obesity and diabetes on high potency injectables, and recommend targeted authorization, paired lifestyle programs, no arbitrary time limits and new payment models. Open source The clearest beneficiary of a rationed market is the gray channel: the University of Mississippi report notes the FDA has issued warning letters over compounded GLP-1s and found sites selling unapproved or incorrect ingredients.3 University of Mississippi 2026-07-22 ICER's 2026 budget impact threshold is $821 million and GLP-1 spending exceeds it even at low uptake; about 40% of American adults have obesity; trials compared GLP-1s against lifestyle management rather than no treatment; the FDA has issued warning letters about compounded GLP-1s. Open source We assess with moderate confidence that every tightening of formal coverage pushes demand toward that channel, because the demand does not disappear when the coverage does.
The counter-case
The strongest argument against reading this as a durable constraint is that the threshold is a convention, not a law of nature. ICER's budget impact threshold is a modeling device designed to flag when a single therapy is absorbing an outsized share of health spending growth; it was not built for a condition affecting two in five adults.3 University of Mississippi 2026-07-22 ICER's 2026 budget impact threshold is $821 million and GLP-1 spending exceeds it even at low uptake; about 40% of American adults have obesity; trials compared GLP-1s against lifestyle management rather than no treatment; the FDA has issued warning letters about compounded GLP-1s. Open source A judgment that a drug for 40% of the population breaks a threshold calibrated to rarer conditions may be describing the tool more than the drug.3 University of Mississippi 2026-07-22 ICER's 2026 budget impact threshold is $821 million and GLP-1 spending exceeds it even at low uptake; about 40% of American adults have obesity; trials compared GLP-1s against lifestyle management rather than no treatment; the FDA has issued warning letters about compounded GLP-1s. Open source
The second counter is competition. ICER itself observed that additional treatment options could help close the treatment gap, and the arrival of more entrants and oral formulations pushes net prices down.5 Pharmaceutical Commerce 2025-10-30 ICER draft cost per quality adjusted life year of $53,400 for tirzepatide, $61,400 for injectable semaglutide and $69,300 for oral semaglutide, with weight loss of 17.8% to 20.8%, 14% to 17% and 11.4% respectively, and a note that additional treatment options may help close the treatment gap. Open source For the affordability thesis to fail, prices would have to fall far enough that the population multiplication stops mattering, or real world persistence and offsets would have to improve enough to make coverage close to spending neutral. The commentary's persistence and offset findings currently point the other way.2 Journal of Managed Care & Specialty Pharmacy 2026-06-01 Ramachandran, Urick and Thomas find weight loss drugs cost effective but high budget impact, note lower real world persistence with weight regain after discontinuation, cost offsets mainly in patients with obesity and diabetes on high potency injectables, and recommend targeted authorization, paired lifestyle programs, no arbitrary time limits and new payment models. Open source Note also that the sharpest figures here come from one assessment body and one commentary reading it, not from independent replications.
What to watch
- Net price versus the benchmark. ICER put justifiable prices for injectable semaglutide at $9,100 to $12,500 against a $6,829 net price.4 ICER 2025-10-29 Net annual prices of $6,829 for injectable semaglutide and $7,973 for tirzepatide; health benefit price benchmarks of $9,100 to $12,500, $8,300 to $11,400 and $11,500 to $15,800; fewer than 1% of eligible patients treatable within an $880 million annual budget impact threshold; access and affordability alert issued. Open source If net prices fall materially below that floor over the next year, competition is doing work that policy has not; if they hold flat, manufacturers are reading the value finding as pricing cover.
- Coverage breadth, not coverage headlines. Watch whether new coverage decisions over the next 12 months are broad or are scoped to obesity plus diabetes on high potency injectables, the subgroup where offsets appeared.2 Journal of Managed Care & Specialty Pharmacy 2026-06-01 Ramachandran, Urick and Thomas find weight loss drugs cost effective but high budget impact, note lower real world persistence with weight regain after discontinuation, cost offsets mainly in patients with obesity and diabetes on high potency injectables, and recommend targeted authorization, paired lifestyle programs, no arbitrary time limits and new payment models. Open source Narrow scoping would confirm payers are following the offset evidence rather than the value headline.
- Persistence data. If published real world persistence rises toward trial levels, the savings case strengthens and the budget objection weakens; continued low persistence with weight regain after discontinuation keeps the offset argument unavailable.2 Journal of Managed Care & Specialty Pharmacy 2026-06-01 Ramachandran, Urick and Thomas find weight loss drugs cost effective but high budget impact, note lower real world persistence with weight regain after discontinuation, cost offsets mainly in patients with obesity and diabetes on high potency injectables, and recommend targeted authorization, paired lifestyle programs, no arbitrary time limits and new payment models. Open source
- Whether the threshold itself is revisited. Track any move to change how budget impact thresholds are applied to high prevalence conditions.3 University of Mississippi 2026-07-22 ICER's 2026 budget impact threshold is $821 million and GLP-1 spending exceeds it even at low uptake; about 40% of American adults have obesity; trials compared GLP-1s against lifestyle management rather than no treatment; the FDA has issued warning letters about compounded GLP-1s. Open source A methodological revision would be the cleanest sign that the constraint was partly an artifact of the tool.
- Enforcement against compounded supply. Further FDA action on compounded GLP-1s would indicate that rationed formal coverage is displacing demand into an unregulated channel.3 University of Mississippi 2026-07-22 ICER's 2026 budget impact threshold is $821 million and GLP-1 spending exceeds it even at low uptake; about 40% of American adults have obesity; trials compared GLP-1s against lifestyle management rather than no treatment; the FDA has issued warning letters about compounded GLP-1s. Open source
The unresolved question is not whether these drugs are worth their price. That has now been answered twice by the same body that flagged the affordability problem.4 ICER 2025-10-29 Net annual prices of $6,829 for injectable semaglutide and $7,973 for tirzepatide; health benefit price benchmarks of $9,100 to $12,500, $8,300 to $11,400 and $11,500 to $15,800; fewer than 1% of eligible patients treatable within an $880 million annual budget impact threshold; access and affordability alert issued. Open source The question is what a health system does when a therapy is simultaneously good value and unaffordable, and every answer available to it, narrower eligibility, staged uptake, or new payment structures, is a rationing decision wearing a different name.